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Abst ract
Since its introduction in 1921, the ketogenic diet has been in
continuous use for children with difficult-to-control epilep-
sy. After decades of relative disuse, it is now both extremely
popular and well studied, with approximately two-thirds of
children demonstrating significant seizure reduction after 
6 months. It is being used for less intractable seizures in chil-
dren as well as recently adults. Modifications that help
improve tolerability include the medium chain triglyceride
diet, modified Atkins diet, and low glycemic index treatment.
Major side effects include acidosis, increased cholesterol, kid-
ney stones, gastroesophageal reflux, and growth disturbance.
However, these side effects are usually treatable and nowa-
days often even preventable. Future non-epilepsy indications
such as Alzheimer disease, amyotrophic lateral sclerosis,
autism, and brain tumors are under active investigation. This
dietary treatment for epilepsy has undergone a rebirth. Its
widespread use in Poland and Europe is a welcome additional
treatment for those with drug-resistant epilepsy.
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St reszc zenie
Dieta ketogenna od jej opracowania w 1921 r. znalaz³a sta³e
miejsce w leczeniu lekoopornej padaczki u dzieci. Po kilku
dekadach wzglêdnego zapomnienia, sta³a siê znowu popu-
larna i szeroko badana – u ok. 2/3 dzieci stwierdza siê istot-
ne zmniejszenie czêstoœci napadów w ci¹gu 6 miesiêcy lecze-
nia. Dieta ketogenna coraz czêœciej jest wykorzystywana
w leczeniu mniej opornych padaczek, a ostatnio tak¿e
u doros³ych. Pojawiaj¹ siê ³atwiej tolerowane odmiany diety:
dieta oparta na œrednio³añcuchowych trójglicerydach, zmo-
dyfikowana dieta Atkinsa czy dieta z niskim wskaŸnikiem gli-
kemicznym. Do g³ównych objawów ubocznych stosowania
tego typu diety nale¿¹: kwasica, hipercholesterolemia, kami-
ca nerkowa, refluks ¿o³¹dkowo-prze³ykowy i zaburzenia wzro-
stu. Powy¿sze objawy uboczne poddaj¹ siê obecnie leczeniu,
a nawet mo¿na im zapobiegaæ. Bardzo aktywnie bada siê
mo¿liwoœci stosowania diety poza padaczk¹: w chorobie
Alzheimera, stwardnieniu zanikowym bocznym, autyzmie
i guzach mózgu. Leczenie padaczki diet¹ prze¿ywa swój rene-
sans. Nale¿y siê spodziewaæ jej szerszego zastosowania w Pol-
sce i Europie u chorych na lekooporn¹ padaczkê.
S³owa kluczowe: dieta ketogenna, padaczka, leczenie.
Introduction
The ketogenic diet (KD) is a high-fat, low-carbo-
hydrate and normal-protein diet which has regained
recognition over the past 15 to 20 years due to its
antiepileptic effect. Typically used in children with
intractable epilepsy, it has also become studied in adults
in the past decade. Recent reports on its beneficial effect
for several metabolic and neurodegenerative disorders
have also increased the interest in its use in neurology.
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Fasting as a therapy for seizures has been known
since biblical times. However, it was not until the early
20th century that the KD was used to mimic the bio-
chemical mechanisms of fasting. The first scientific
reports on the value of fasting and water diets in epilep-
sy were authored by Guelpa and Marie, both French
physicians, in 1911 [1], but it was not until the 1921
American Medical Association convention, at which
Rawle Geyelin, an eminent American pediatrician
declared successful treatment of epilepsy by fasting, that
this method of treatment gained the attention of medi -
cal professionals. Geyelin reported a case of a 10-year-
old boy who had frequent seizures for the last 4 years
and was successfully treated by an osteopath, Dr. Hugh
Conklin. Repeated 15-day periods of fasting resulted in
long-term cessation of seizures [2].
For the next 20 years, mainly due to researchers at
the Mayo Clinic in Rochester, the ketogenic diet became
a well-recognized method of treatment for patients with
epilepsy. Introduction of phenytoin in 1938, at the time
a new antiepileptic drug, which could be more easily
applied than a diet, hindered the use of the ketogenic
diet for more than five decades. 
The diet has regained recognition over the past 15 to
20 years, largely due to the Charlie Foundation and their
movie First, do no harm (1997) depicting a boy with
drug-resistant epilepsy successfully treated with KD and
starring Meryl Streep. Since then, an enormous growth
of interest in the KD has been noted. A PubMed search
made on 29th December 2010 indicates a nearly 6-fold
increase of the number of peer-reviewed articles on the
KD in the last decade compared to the previous one
(828 : 144). In 2006, for the first time ever, separate ses-
sions on KD were organized during the International
Child Neurology Association and Child Neurology
Society annual meetings. In 2008 and 2010, two large
conferences dedicated solely to this kind of treatment
took place in Phoenix, Arizona and Edinburgh, Scot-
land, hosting several hundred attendees. 
The KD is now available in at least 50 countries
worldwide [3]. The growing number of centers work-
ing with KD resulted in the first recommendations, writ-
ten by 26 neurologists and dieticians from 9 countries,
which were published in Epilepsia in November 2008 [4]. 
Ketogenic diet and its modifications
The classic KD, also called the long-chain trigly ce -
ride diet, is high in fat, adequate for protein (1 g/kg per
day) and low in carbohydrate. The fat calories come not
only from butter and mayonnaise, but also from a vari-
ety of oils, olives, etc. The diet is traditionally calorie
limited and most frequently is started in the hospital after
1 or 2 days of fasting. Fasting is no longer regarded as
necessary for starting the KD, but it helps to obtain
ketotic status in a shorter time. Also fluid restriction is
no longer considered necessary.
The classic KD is calculated in a ratio of grams of
fat to grams of protein and carbohydrate combined. The
ratio ranges from 2 : 1 to 4 : 1. The most common diet,
“4 : 1” (4 grams of fat to 1 gram of protein plus carbo-
hydrate), is regarded as the most restrictive but the most
effective. The fat, the main source of calories, is obtained
from standard foods. Calories cover initially 80% to 90%
of the daily recommendations for age but are frequent-
ly adjusted over time to ensure ideal growth. 
In the search for better palatability, the medium-
chain triglyceride (MCT) diet was developed in 1971
[5]. In the traditional MCT diet 60% of the total calo-
rie prescription was provided by MCT oils. Due to its
higher ketogenic effect the MCT diet allowed libera -
lization of carbohydrate content in the diet. 
The high proportion of patients with gastrointesti-
nal discomfort with abdominal cramps, diarrhea and
vomiting prompted the researchers to modify the MCT
diet and reduce MCTs to 30% of calories, replacing
them with 30% long-chain fat (‘modified MCT diet’).
This kind of diet turned out to be more expensive and
less affordable for families. Recent studies have shown
both diets to be equivalent [6]. 
In the past decade two other modifications of KD
have been developed for epilepsy treatment: low-
glycemic-index treatment (LGIT) and the modified
Atkins diet [7,8]. Both diets are high in fat and restric-
tive in carbohydrate, but unlike the classic KD may be
initiated in outpatient settings and do not require pre-
cise weighing of food ingredients and portions. 
LGIT allows liberalization of carbohydrate intake
to approximately 40-60 g/day with glycemic indices 
< 50 used for the carbohydrates. The modified Atkins
diet is very similar to KD with high fat and low carbo-
hydrate and approximately 1:1 ketogenic ratio. The ini-
tial carbohydrate intake is approximately 10 g for chil-
dren (20 g per day for adults), and all carbohydrates
(although limited) are allowed. The lack of limitations
on protein, fluids and calories helps improve the palata-
bility of the diet [9]. According to the International
Ketogenic Diet Study Group both LGIT and the modi -
fied Atkins diet may be particularly advantageous for
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adolescents and adults [4,10]. The aforementioned diets
are characterized in Table 1. 
How does the diet work?
Despite nearly 100 years of use, the mechanism of
antiepileptogenic action of KD remains unclear [11].
Broad spectrum efficacy of KD against heterogeneous
seizure types and epileptic syndromes indicates that the
diet must work through a common molecular pathway
responsible for neuronal hyperexcitability and hyper-
synchrony. 
Early studies suggested that the suppression of epi -
leptic activity is related to the degree of ketosis, as a con-
sequence of increased fatty acid oxidation. There is no
study to show a correlation between urine ketones and
seizure control. The only study, by Gilbert et al. [12],
showed that seizure control correlates better with serum
β-hydroxybutyrate than with urine ketones. 
Yet, in 1933 Keith [13] reported in normal rabbits
a protective effect of acetoacetate in seizures induced by
thujone, a GABAA receptor antagonist. More recently
Likhodii et al. [14] proved that acute administration of
acetoacetate and acetone blocked seizure activity induced
by maximal electroshock and pentylenetetrazole in nor-
mal rats. However, there is no direct effect, even if some
experimental studies may justify such an assumption. 
It has also been shown that the KD can increase lev-
els of ATP and other bioenergetic substrates through
enhanced mitochondrial respiration [15]. Still, as high
ATP levels block surface ATP-sensitive potassium chan-
nels, it remains unclear how the infusion of ketone bod-
ies in the substantia nigra pars reticulata may result in
their opening. 
Masino et al. [16] stress the role of adenosine, the
core molecule of ATP, in antiepileptic mechanism of
KD. According to the authors such metabolic and die -
tary strategies as KD may increase regional or global
adenosine and increase the overall seizure threshold.
Also some other agents have been studied as poten-
tial factors influencing KD effectiveness. 2-deoxyglu-
cose, an inhibitor of phosphoglucose isomerase, an
enzyme converting glucose-6-phosphate to fructose-
6-phosphate, has been shown to be effective in multiple
types of animal models of seizures and in kindling mod-
els of temporal lobe epilepsy [17,18]. 
Despite the multiple working hypotheses the under-
lying mechanisms of antiepileptic effect of the KD
remain to be confirmed. 
Efficacy of ketogenic diet 
in childhood epilepsy
The KD is an effective nonpharmacological treat-
ment for patients, particularly children, with drug-resis-
tant epilepsy, both partial and generalized. In compari-
son to vagus nerve stimulation (VNS), another major
nonpharmacological treatment for intractable epilepsy,
the KD appears to work faster, usually within 2 to 
4 weeks, compared to several months when on VNS
[19]. Both treatments are typically used after 2-3 drugs
have failed and if surgery is not a straightforward option.
Some epileptologists believe that the KD may be one
of the most effective therapies in childhood epilepsy
[20]. Its effectiveness has been documented in infan-
tile spasms [21,22], Lennox-Gastaut syndrome [23],
Dravet syndrome [24] myoclonic-astatic epilepsy of ear-
ly childhood [25,26], and absence epilepsy [27]. 
It should be noted that during its history the KD
has been used almost exclusively for intractable epilep-
sy after multiple anticonvulsants have been tried unsuc-
cessfully. It is commonly recognized that in such
patients the probability of successful treatment is often
extremely low. Even in these patients the KD is highly
effective, resulting in greater than 50% improvement
in seizure frequency in two-thirds of those treated, and
complete cessation of seizures in 7-23% [28-30].
Therefore, it seems to be well justified that the KD
should be consi dered after no more than two anticon-
vulsants have been tried, not five or more as is fre-
quently the case. Such a recommendation has been
recently issued by the International Ketogenic Diet
Study Group [4].
Diet Fat (g) Protein (g) Carbohydrate (g)
Classic 4 : 1 100 17 8
Classic 3 : 1 96 18 14
Classic 2 : 1 92 20 26
Classic 1 : 1 77 37 40
Medium-chain 78 25 50
triglyceride oil diet
Low-glycemic-index 67* 40-60* 40-60
treatment
Modified Atkins diet 72* 68-78* 10-20
Table 1. Characteristics of the classic ketogenic diet and its modifications
(1000 kcal/d  provided) (adapted from [10])
*Approximate values
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Until 2008 there existed only open label cohort stud-
ies on the efficacy of the KD in intractable epilepsies.
A Cochrane review in 2003 reviewed 14 studies, but
reported a lack of reliable randomized controlled trials
which might support the use of the KD [31]. The au -
thors concluded that ‘for those with a difficult epilepsy
on multiple antiepileptic drugs, we consider the keto-
genic diet a possible option’.
There are 3 other major meta-analyses of the effica-
cy of the KD, all of which conclude that despite the lack
of controlled, randomized studies, there is clear evidence
of KD efficacy [32-34]. The first meta-analysis, per-
formed by Lefevre and Aronson, systematically reviewed
11 studies (9 from a single institution), all observation-
al and only two prospective. Fifty-six percent of patients
had >50% reduction in seizures and 32% had > 90%
seizure reduction [32]. In 2006, two meta-analyses were
published. In his review, Keene [33] included 14 stud-
ies with at least 6 months follow-up since KD initiation.
In the total cohort of 972 patients at 6-month follow-
up 15.6% were seizure-free and 33% of children had
more than 50% reduction of seizures. Similarly, Hen-
derson et al. [34] reviewed 19 studies with a follow-up
of at least 6 months, providing a total of 1084 patients.
The authors confirmed that the KD reduced seizures
by >90% in a third of the patients and by >50% in half.
All authors of the meta-analyses stressed the lack of class
I and class II data.  
In 2008 Neal et al. conducted at the Institute for
Child Health in London the first randomized controlled
trial on efficacy of KD in childhood epilepsy [35]. One
hundred forty-five patients aged between 2 and 16 years
who had at least daily seizures and had failed to respond
to at least 2 antiepileptic drugs participated in the study.
Children were randomly assigned to receive the KD,
either immediately or after a 3-month delay, with no 
other changes to treatment (control group). The obtained
data documented responder rates (>50% improvement
in seizure frequency) on an intention-to-treat basis of
38% when compared with 6% of the control group.
Moreover, 7% of the patients in the diet group had
greater than 90% seizure reduction compared with none
in the control group. The KD group was further ran-
domized to receive either MCT or the classical KD. No
difference was seen in efficacy between the classical and
MCT diets [6].
Another randomized controlled and also a double
blind study specific for Lennox-Gastaut syndrome was
published in 2009 by researchers from Johns Hopkins
Hospital [23]. The children, aged 1 to 10 years, were
initially fasted and subsequently clinical and electroen-
cephalographic events were documented. Half of them
received a saccharin drink and another half a glucose
drink, those with the latter assumed to break ketosis.
Parents and physicians were blinded, both to the solu-
tion composition and level of ketosis. On the 6th day the
children were reexamined. Seizure count and control
EEG were performed and children were crossed over
to receive the alternative drink. The study was finished
after another 6 days with seizure control and EEG
reevaluation. Comparing baseline seizure frequency to
day 12, there was a significant reduction in seizures with
a median decrease of –34 seizures per day (p= 0.003).
Sixty-five percent of patients experienced >50% reduc-
tion in seizures over the study period. Unfortunately, for
multiple reasons, the difference between the saccharin
(treatment) and glucose (placebo) groups only neared
statistical significance (p= 0.07).
There are only a few papers analyzing the efficacy of
the KD in different seizure types. The KD seems to be
more efficient in focal than in generalized epilepsies [36]. 
The KD is also helpful for many children in medi -
cation reduction, improving cognitive function, and
often alertness. Kossoff et al. [37] recommend reduc-
ing medications after the first month to ensure the diet
is being effective, then choosing one medication at a time
and reducing it slowly.
Some reports have described improvement in the
EEG, but this has never been fully demonstrated
prospectively. The majority of children will continue 
the KD for approximately 2 years if successful, and 
3-6 months if it is not. [38]. The KD is typically weaned
over a 2-4 month period.[4].
Efficacy of ketogenic diet 
in adulthood epilepsy
The history of the KD for adults is also not a new
idea, despite the recent interest. The first study, in 
100 adults, was performed in 1930 by Barborka [39].
After one year of treatment with KD monotherapy 
12% of patients became seizure-free, 44% improved and
44% remained unchanged. Recently, four reports have
been published on classical KD treatment of epilepsy in
adolescents and adults [40-43]. 
The efficacy of KD in these studies is similar to that
observed in pediatric cohorts. These data suggest that
the KD may be very effective in a proportion of adults.
The reason why the KD was rarely used in adults was
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a general opinion that the diet is restrictive and unpalat-
able and its preparation is complex and time-consum-
ing. In addition, many adults will tend to be noncom-
pliant if they are not seizure-free (and likely not driving).
Therefore non-compliance may be a major problem in
adult patients. 
Looking for a more palatable and less restrictive diet
for adult patients, three groups of investigators studied
the effectiveness of the modified Atkins diet in epilepsy
[44-46]. In one study of 30 patients 33% of them
achieved a 50% seizure reduction at 6 months, one pa -
tient was seizure-free, and 33% stopped treatment after
a 3-month period [44]. In another small series of 
8 patients, 3 continued a diet for 6 months with the fol-
lowing seizure reduction: > 50%, > 30% and < 30%
[45]. A recent study from Toronto reported 4/18 (22%)
with > 50% seizure reduction after 6 months [46].
Ketogenic diet in other indications
Except for epileptic syndromes there is a growing
list of conditions in which the KD was found to have
a beneficial effect (Table 2).
Nowadays, the KD is a recognized treatment of
choice in two distinct disorders of brain energy meta -
bolism: glucose transporter protein type 1 (GLUT-1)
deficiency syndrome and pyruvate dehydrogenase defi-
ciency (PDHD) [4].
GLUT-1 deficiency syndrome is characterized by
impaired glucose transport across the blood-brain bar-
rier resulting in seizures, developmental delay and com-
plex movement disorders observed in infants and small
children [47,48]. 
In PDHD pyruvate cannot be metabolized into
acetyl-CoA, leading to a heterogeneous clinical picture,
usually characterized by hypotonia, lethargy, apnea and
seizures [49,50]. The diagnosis is made by document-
ing an elevation of lactate and pyruvate in cerebrospinal
fluid. In both conditions the KD provides ketones that
bypass the metabolic defect and serve as an alternative
fuel to the brain [4]. 
There is an increasing number of reports on the use
of KDs in different neurological conditions with symp-
tomatic epilepsy, such as Lafora body disease [51],
Angelman syndrome [52], Landau-Kleffner syndrome
[53], Sturge-Weber syndrome [54], subacute scleros-
ing panencephalitis (SSPE) [55], Rett syndrome [56,
57], and tuberous sclerosis [58].
There are single reports describing the use of KDs
in some rare metabolic conditions: glycogenosis type V
[59,60], phosphofructokinase deficiency [61], and
mitochondrial respiratory chain complex disorders [62].
The beneficial effect of the KD has also been reported
in schizophrenia. The authors suggested a possible role
of a gluten-free diet in ameliorating schizophrenic symp-
toms [63].
In 2010 there appeared in the medical literature
reports indicating a role of KDs in the regression of
brain tumors. The study of Stafford et al. [64] demon-
Evidenced benefit/probable benefit
Epileptic syndromes
Infantile spasms
Severe myoclonic epilepsy of infants (Dravet syndrome)
Myoclonic-astatic epilepsy (Doose syndrome)
Lennox-Gastaut syndrome
Metabolic conditions
Glucose transporter protein 1 (GLUT-1) deficiency
Pyruvate dehydrogenase deficiency (PDHD)
Neurodegenerative disorders
Rett syndrome
Tuberous sclerosis
Children receiving only formula (infants or enterally fed patients)
Suggestion of benefit
Selected mitochondrial disorders
Glycogenosis type V
Landau-Kleffner syndrome
Lafora body disease
Subacute sclerosing panencephalitis (SSPE)
Angelman syndrome
Sturge-Weber syndrome
Phosphofructokinase deficiency
Undetermined benefit
Schizophrenia
Brain tumors
Amyotrophic lateral sclerosis
Parkinson disease
Alzheimer disease
Migraine
Table 2. Indications for the ketogenic diet (adapted with modifications from [4])
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strated that the KD improves survivability in a mouse
model of glioma. Zuccoli et al. [65] reported of an adult
patient with glioblastoma multiforme who experienced
regression of the tumor after a two-month restrictive
KD with vitamin and mineral supplementation. MRI
evidence of tumor recurrence was found 10 weeks after
suspension of strict diet therapy. The concept of this
application of KD is to shift the prime substrate for ener-
gy metabolism from glucose to ketone bodies in order
to disrupt tumor metabolism while maintaining the
nutritional status of patients [66] . 
There are several animal model studies and uncon-
trolled trials suggesting the potential benefits of the KD
in amyotrophic lateral sclerosis, Parkinson disease, 
mi graine, autism, and narcolepsy [2]. However, due to
a lack of sufficient evidence of efficacy, at this time, the
use of KD in these indications cannot currently be re-
commended [4].
Henderson et al. [67] reported significant improve-
ment of cognitive performance in patients with Alz -
heimer disease treated with the ketogenic agent AC 1202
in a randomized, double blind, placebo-controlled trial
[67]. Currently available in the United States is a pro -
duct called “Axona” that is MCT oil based as a treat-
ment for Alzheimer disease.
Contraindications and safety 
measures
The KD is contraindicated in several specific disor-
ders (Table 3). The shift of the primary energy source
from carbohydrates to ketones may result in severe cata-
bolic crisis in patients with impaired fat metabolism.
Therefore clinical suspicion of an inborn error of meta -
bolism (developmental delay, hypotonia, exercise intole-
rance, myoglobinuria, cardiomyopathy) requires addi-
tional testing to exclude the metabolic condition prior
to initiation of the KD. Laboratory tests and additional
investigations required for pre-KD evaluation are pre-
sented in Table 4. 
Admission to the hospital is recommended at the
beginning of the diet for monitoring in case of metabolic
problems, handling acidosis, vomiting or hypoglycemia.
It is also helpful to carry out intensive educative work
with parents or caregivers.
Patients who start the KD may present early or late
onset side effects. The first may be observed during the
initiation of the diet. Dehydration, frequently caused by
fluid restriction, hypoglycemia, acidosis, vomiting, diar-
rhea or refusal to eat may be secondary to either the fast
or the diet itself. Gastrointestinal symptoms (e.g. reflux)
occur in 12-50% of children [68,69].
Some studies indicate significant increase of LDL,
VLDL and non-HDL cholesterol and decrease of
HDL cholesterol after 6 months of treatment. It should
be noted that significant but less marked changes were
Primary carnitine deficiency
Carnitine palmitoyltransferase I or II deficiency
Carnitine translocase deficiency
Pyruvate carboxylase deficiency
β-oxidation defects :
Medium-chain acyl dehydrogenase deficiency (MCHAD)   
Long-chain acyl dehydrogenase deficiency (LCHAD)
Short-chain acyl dehydrogenase deficiency (SCHAD)
Long-chain 3-hydroxyacyl-CoA deficiency
Medium chain 3-hydroxyacyl-CoA deficiency
Porphyria
Table 3. Definite contraindications to the ketogenic diet (adapted from [4])
Laboratory tests 
Complete blood count with platelets
Electrolytes to include serum bicarbonate, total protein, 
calcium, zinc, selenium, magnesium, and phosphate
Serum liver and kidney tests (including albumin, AST, ALT, 
blood urea nitrogen, creatinine)
Fasting lipid profile
Serum acylcarnitine profile
Urinalysis
Urine calcium and creatinine
Anticonvulsant drug levels (if applicable)
Urine organic acids
Serum amino acids
Ancillary investigations (optional)
Renal ultrasound and nephrology consultation 
(if a history of kidney stones)
Electroencephalography
Magnetic resonance imaging
Cerebrospinal fluid analysis (if no clear etiology identified)
Electrocardiogram, if history of heart disease
Table 4. Laboratory tests and additional investigations required for pre-keto-
genic diet evaluation (adapted with modifications from [4])
Dietary treatment of epilepsy
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observed in these children after 12 and 24 months of
the diet [70]. 
The KD does not influence the blood level of
antiepileptic drugs [71].
During the maintenance phase particular attention
should be paid to renal stones, delayed somatic growth
with hypoproteinemia, increased infections or cardiac
complications. Kidney stones have been reported in 
3-7% of children on KD. Their formation may be relat-
ed to hypercalciuria and hypocitraturia, which may also
result from the KD. Fluid restriction is an additional
promoting factor. Oral potassium citrate is an effective
preventive supplement against kidney stones, reducing
the risk 7-fold [72].
Alimentary restrictions of the KD may also lead to
delayed somatic growth particularly expressed in small
children. Neal et al. [73] assessed in up to 12 months
follow-up 75 children on the KD and MCT diet and
confirmed that both weight and height z scores
decreased during the diet. There was no difference in
outcome between classical and medium-chain trigly -
ceride protocols despite the increased protein in the lat-
ter diet. Growth appears to improve after the KD is dis-
continued [74].
In order to prevent the delay of somatic growth while
on KD, strict nutritional monitoring has been proposed
by the International Ketogenic Diet Study Group with
the assessment of protein intake [4]. Some vitamins and
minerals which are lacking in the KD should also be
supplemented. This is particularly important with re -
spect to vitamins D and B and calcium [75]. There is
no evidence to recommend extra supplementation of
zinc, selenium, magnesium or phosphorus, but routine
vitamins need to be ensured [4] (Table 5). 
Increased infections have been reported in 2-4% of
children on the KD. While on the diet, the patients may
demonstrate abnormal neutrophil functions with
impaired bacterial phagocytosis and killing [76]. 
Cardiomyopathy and prolonged QT interval have
been reported in a few children on the KD. Selenium
deficiency was disclosed as their potential cause, but was
not confirmed in other studies. Best et al. [77] postu-
lated that a greater degree of acidosis and a higher 
β-hydroxybutyrate level might lead to the cardiac abnor-
malities. 
Conclusions
The KD is an effective treatment for refractory
epilepsy, particularly in childhood. The efforts to make
it more palatable led to several modifications. The in -
creasing interest in KD observed in the last 2 decades
led to many new indications. 
However, as with many other medical therapies, the
KD also has its side effects. Their recognition is very
important for proper monitoring of children for devel-
opment of these complications. 
In the era of the internet the dietetic services, sup-
ported by such charity organizations as Matthew’s
Friends, The Charlie Foundation, or the Daisy Garland
Trust, are a source of new diets and advice for parents
or caregivers. Culture-specific diets have been designed
to meet the needs of a wide variety of cultures and
nations. The KDs have proven to be an effective treat-
ment in epilepsy and should be considered in all cases
of drug-resistant seizures. The establishment of spe-
cialized KD centers would help to conduct this kind of
treatment in a more efficient and safe way. 
Disclosure
Dr. Kossoff is on the Scientific Advisory Board for
Atkins Nutritionals, Inc.
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